REGN: Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis

New alert via PocketInfo for REGN:

Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis

Press Releases: http://investor.regeneron.com/releases.cfm
SEC Filings: http://investor.regeneron.com/sec.cfm
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8